SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it has been awarded a 2018 Top Workplaces honor by the Bay Area News Group. This marks the fifth consecutive year that Veracyte has received this prestigious award, which is based solely on the results of an annual survey of Bay Area-company employees.
“Receiving this honor for the fifth time validates the great culture our team has created at Veracyte,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “We work very hard to ensure every one of our employees understands our mission to improve patient care and their absolute importance in helping us achieve it. This prestigious award is a reflection of this daily effort, as well as the pride our employees take in our company and the work we do.”
The Top Workplaces award winners are determined by results of an employee feedback survey administered by WorkplaceDynamics, LLC, a leading research firm that specializes in organizational health and workplace improvement. Several key aspects of workplace culture were measured for the award, including organizational alignment, effective execution and meaningful connection with employees.
The Bay Area News Group published the complete list of 2018 Top Workplaces on Sunday, June 24. The list of winners is available at the Bay Area News Group website.
Veracyte’s corporate and industry leadership has been recognized consistently over the past several years. In 2017, Ms. Anderson received the 2017 Wallace H. Coulter Award for Healthcare Innovation from the Biomedical Engineering Society and was named one of the “Fiercest Women in Life Sciences” by FierceBiotech. In 2016, the company received the prestigious Edison Award honoring excellence in new product and service development, marketing, human-centered design and innovation.
Veracyte, Inc. (Nasdaq: VCYT) is a leading genomic diagnostics company that is providing trustworthy and actionable answers that fundamentally improve patient care when current diagnostic tests are uncertain. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).